These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33721619)

  • 1. A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry.
    Li X; Larsson P; Ljuslinder I; Ling A; Löfgren-Burström A; Zingmark C; Edin S; Palmqvist R
    Pathol Res Pract; 2021 Apr; 220():153379. PubMed ID: 33721619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Classification of Colorectal Cancer in Molecular Subtypes by Immunohistochemistry.
    Ten Hoorn S; Trinh A; de Jong J; Koens L; Vermeulen L
    Methods Mol Biol; 2018; 1765():179-191. PubMed ID: 29589308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simple classifiers for molecular subtypes of colorectal cancer.
    Kim WG; Kim JY; Park DY
    Arab J Gastroenterol; 2017 Dec; 18(4):191-200. PubMed ID: 29241727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry.
    Trinh A; Trumpi K; De Sousa E Melo F; Wang X; de Jong JH; Fessler E; Kuppen PJ; Reimers MS; Swets M; Koopman M; Nagtegaal ID; Jansen M; Hooijer GK; Offerhaus GJ; Kranenburg O; Punt CJ; Medema JP; Markowetz F; Vermeulen L
    Clin Cancer Res; 2017 Jan; 23(2):387-398. PubMed ID: 27459899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
    Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
    Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus molecular subtype classification of colorectal adenomas.
    Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
    J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of TSPAN8 in consensus molecular subtype 3 colorectal cancer.
    Suwatthanarak T; Tanjak P; Chaiboonchoe A; Acharayothin O; Thanormjit K; Chanthercrob J; Suwatthanarak T; Niyomchan A; Tanaka M; Okochi M; Pongpaibul A; Chalermwai WV; Trakarnsanga A; Methasate A; Pithukpakorn M; Chinswangwatanakul V
    Exp Mol Pathol; 2024 Jun; 137():104911. PubMed ID: 38861838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2.
    Chang K; Willis JA; Reumers J; Taggart MW; San Lucas FA; Thirumurthi S; Kanth P; Delker DA; Hagedorn CH; Lynch PM; Ellis LM; Hawk ET; Scheet PA; Kopetz S; Arts J; Guinney J; Dienstmann R; Vilar E
    Ann Oncol; 2018 Oct; 29(10):2061-2067. PubMed ID: 30412224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
    Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
    Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer.
    Mochizuki K; Kudo SE; Kato K; Kudo K; Ogawa Y; Kouyama Y; Takashina Y; Ichimasa K; Tobo T; Toshima T; Hisamatsu Y; Yonemura Y; Masuda T; Miyachi H; Ishida F; Nemoto T; Mimori K
    PLoS One; 2022; 17(10):e0273566. PubMed ID: 36264865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A consensus molecular subtypes classification strategy for clinical colorectal cancer tissues.
    de Back TR; Wu T; Schafrat PJ; Ten Hoorn S; Tan M; He L; van Hooff SR; Koster J; Nijman LE; Vink GR; Beumer IJ; Elbers CC; Lenos KJ; Sommeijer DW; Wang X; Vermeulen L
    Life Sci Alliance; 2024 Aug; 7(8):. PubMed ID: 38782602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
    Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
    Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A panel of DNA methylation markers for the classification of consensus molecular subtypes 2 and 3 in patients with colorectal cancer.
    van den Berg I; Smid M; Coebergh van den Braak RRJ; van de Wiel MA; van Deurzen CHM; de Weerd V; Martens JWM; IJzermans JNM; Wilting SM
    Mol Oncol; 2021 Dec; 15(12):3348-3362. PubMed ID: 34510716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic subtypes predict outcomes in colorectal cancer.
    Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
    Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
    Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting.
    Morris JS; Luthra R; Liu Y; Duose DY; Lee W; Reddy NG; Windham J; Chen H; Tong Z; Zhang B; Wei W; Ganiraju M; Broom BM; Alvarez HA; Mejia A; Veeranki O; Routbort MJ; Morris VK; Overman MJ; Menter D; Katkhuda R; Wistuba II; Davis JS; Kopetz S; Maru DM
    Clin Cancer Res; 2021 Jan; 27(1):120-130. PubMed ID: 33109741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a miRNA-based classifier for detection of colorectal cancer molecular subtypes.
    Adam RS; Poel D; Ferreira Moreno L; Spronck JMA; de Back TR; Torang A; Gomez Barila PM; Ten Hoorn S; Markowetz F; Wang X; Verheul HMW; Buffart TE; Vermeulen L
    Mol Oncol; 2022 Jul; 16(14):2693-2709. PubMed ID: 35298091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RHBDD1 promotes colorectal cancer metastasis through the Wnt signaling pathway and its downstream target ZEB1.
    Zhang M; Miao F; Huang R; Liu W; Zhao Y; Jiao T; Lu Y; Wu F; Wang X; Wang H; Zhao H; Ju H; Miao S; Wang L; Song W
    J Exp Clin Cancer Res; 2018 Feb; 37(1):22. PubMed ID: 29426364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer.
    Lal N; White BS; Goussous G; Pickles O; Mason MJ; Beggs AD; Taniere P; Willcox BE; Guinney J; Middleton GW
    Clin Cancer Res; 2018 Jan; 24(1):224-233. PubMed ID: 29061646
    [No Abstract]   [Full Text] [Related]  

  • 20. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
    Soldevilla B; Carretero-Puche C; Gomez-Lopez G; Al-Shahrour F; Riesco MC; Gil-Calderon B; Alvarez-Vallina L; Espinosa-Olarte P; Gomez-Esteves G; Rubio-Cuesta B; Sarmentero J; La Salvia A; Garcia-Carbonero R
    Eur J Cancer; 2019 Dec; 123():118-129. PubMed ID: 31678770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.